Genmab A/S (NASDAQ:GMAB) Sees Large Drop in Short Interest

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,620,000 shares, a decline of 6.4% from the January 15th total of 1,730,000 shares. Currently, 0.3% of the company's shares are sold short. Based on an average daily volume of 1,370,000 shares, the days-to-cover ratio is presently 1.2 days.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Creative Planning boosted its stake in Genmab A/S by 136.3% during the third quarter. Creative Planning now owns 47,422 shares of the company's stock worth $1,156,000 after buying an additional 27,353 shares during the last quarter. Bleakley Financial Group LLC boosted its stake in Genmab A/S by 7.7% during the third quarter. Bleakley Financial Group LLC now owns 30,732 shares of the company's stock worth $749,000 after buying an additional 2,196 shares during the last quarter. Blue Trust Inc. boosted its stake in Genmab A/S by 892.0% during the third quarter. Blue Trust Inc. now owns 4,315 shares of the company's stock worth $108,000 after buying an additional 3,880 shares during the last quarter. Raymond James & Associates boosted its stake in Genmab A/S by 2.2% during the third quarter. Raymond James & Associates now owns 169,747 shares of the company's stock worth $4,138,000 after buying an additional 3,598 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock worth $113,000 after buying an additional 1,413 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Performance

NASDAQ:GMAB traded down $0.10 during mid-day trading on Friday, hitting $22.34. 1,052,865 shares of the company's stock traded hands, compared to its average volume of 1,565,914. The company has a fifty day moving average of $20.68 and a 200 day moving average of $22.97. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The company has a market capitalization of $14.78 billion, a P/E ratio of 12.84, a P/E/G ratio of 2.59 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GMAB shares. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. BMO Capital Markets restated an "outperform" rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $42.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.